Dr. Darnell is an expert in the treatment of B- and T-cell lymphomas and chronic lymphocytic leukemia (CLL). He has a special interest in clinical investigation of novel agents for the treatment of lymphoma including CAR T-cell therapy, bispecific antibodies, targeted therapies, and other immune therapies. He leads research in the development of novel CAR T-cell therapies and is an investigator for efforts to use combinatorial therapy with CAR T-cells to overcome resistant lymphomas. He is additionally interested in the immunologic consequences of CLL and leads an effort to develop a functional characterization of immunity to guide infection prevention in patients with CLL.
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
PMID: 41733967
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer.
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
PMID: 41372740
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma.
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct; 646(8086):953-962.
PMID: 40993381
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency.
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency. Cancer Immunol Res. 2025 Aug 01; 13(8):1132-1144.
PMID: 40455064
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma.
A prospective study of prophylactic dexamethasone with glofitamab in relapsed/refractory large B-cell lymphoma. Blood Neoplasia. 2025 Nov; 2(4):100147.
PMID: 41424939
IFN-?-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models.
IFN-?-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models. Sci Transl Med. 2025 Jun 04; 17(801):eadp8166.
PMID: 40465687
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence.
IgG testing, immunoglobulin replacement therapy, and infection outcomes in patients with CLL or NHL: real-world evidence. Blood Adv. 2024 Aug 27; 8(16):4239-4249.
PMID: 38904477
Tumor burden in ZUMA-7: less is more.
Tumor burden in ZUMA-7: less is more. Blood. 2024 Jun 13; 143(24):2441-2442.
PMID: 38869918
Context matters: Tumor microenvironments impact cellular therapy success.
Context matters: Tumor microenvironments impact cellular therapy success. Cell Rep Med. 2024 Apr 16; 5(4):101491.
PMID: 38631291
Two years later: CD19 CAR-T going the distance.
Two years later: CD19 CAR-T going the distance. Blood. 2024 Feb 01; 143(5):379-380.
PMID: 38300610